FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2968865251> ?p ?o ?g. }

• W2968865251 endingPage "124" @default.
• W2968865251 startingPage "118" @default.
• W2968865251 abstract "The treatment of multiple myeloma (MM) has evolved significantly in the past decade, and new drug combinations have improved the response rates and prolonged survival. Studies comparing different induction chemotherapy regimens have shown that triple combinations have better results than double combinations. However, comparisons among different triple combinations are rare in the literature. We retrospectively compared two triple combinations comprising bortezomib, cyclophosphamide and dexamethasone (VCD) versus thalidomide, cyclophosphamide and dexamethasone (CTD), and aimed at identifying which of the two combinations would yield better response rates following four induction cycles prior to hematopoietic cell transplantation in patients with untreated multiple myeloma. We retrospectively reviewed the medical records of 311 patients from 24 different centers.The VCD regimen was used as induction therapy by 117 (37.6%) patients, whereas 194 (62.4%) patients received the CTD regimen. After four cycles of induction on an intention-to-treat basis, 54% of the patients in the VCD group achieved at least very good partial response versus 42.8% in the CTD group (p = 0.05). We observed no difference in neuropathy or thrombotic events rates among the two regimens. Our results corroborate the superiority of the triple combination regimes containing bortezomib over the triple combination with thalidomide as pre ASCT induction therapy in MM." @default.
• W2968865251 created "2019-08-22" @default.
• W2968865251 creator A5003069566 @default.
• W2968865251 creator A5005131876 @default.
• W2968865251 creator A5005692190 @default.
• W2968865251 creator A5006531968 @default.
• W2968865251 creator A5016817730 @default.
• W2968865251 creator A5020721777 @default.
• W2968865251 creator A5024217548 @default.
• W2968865251 creator A5031247732 @default.
• W2968865251 creator A5036040616 @default.
• W2968865251 creator A5049870109 @default.
• W2968865251 creator A5052746767 @default.
• W2968865251 creator A5053223983 @default.
• W2968865251 creator A5053940370 @default.
• W2968865251 creator A5060838933 @default.
• W2968865251 creator A5063050740 @default.
• W2968865251 creator A5065234124 @default.
• W2968865251 creator A5071336872 @default.
• W2968865251 creator A5071788036 @default.
• W2968865251 creator A5071939716 @default.
• W2968865251 creator A5077757435 @default.
• W2968865251 creator A5079888031 @default.
• W2968865251 creator A5079948354 @default.
• W2968865251 creator A5081443430 @default.
• W2968865251 creator A5087643252 @default.
• W2968865251 date "2020-04-01" @default.
• W2968865251 modified "2023-10-17" @default.
• W2968865251 title "Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation" @default.
• W2968865251 cites W1586223754 @default.
• W2968865251 cites W2015003025 @default.
• W2968865251 cites W2020298011 @default.
• W2968865251 cites W2028195916 @default.
• W2968865251 cites W2035035521 @default.
• W2968865251 cites W2036200625 @default.
• W2968865251 cites W2044436186 @default.
• W2968865251 cites W2050829096 @default.
• W2968865251 cites W2055338149 @default.
• W2968865251 cites W2070790769 @default.
• W2968865251 cites W2071434932 @default.
• W2968865251 cites W2121399230 @default.
• W2968865251 cites W2142368474 @default.
• W2968865251 cites W2148188974 @default.
• W2968865251 cites W2150254829 @default.
• W2968865251 cites W2164807675 @default.
• W2968865251 cites W2165974443 @default.
• W2968865251 cites W2169183166 @default.
• W2968865251 cites W2319764074 @default.
• W2968865251 cites W2425909334 @default.
• W2968865251 cites W2567188480 @default.
• W2968865251 cites W2625865878 @default.
• W2968865251 doi "https://doi.org/10.1016/j.htct.2019.05.004" @default.
• W2968865251 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7248497" @default.
• W2968865251 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31537476" @default.
• W2968865251 hasPublicationYear "2020" @default.
• W2968865251 type Work @default.
• W2968865251 sameAs 2968865251 @default.
• W2968865251 citedByCount "2" @default.
• W2968865251 countsByYear W29688652512022 @default.
• W2968865251 countsByYear W29688652512023 @default.
• W2968865251 crossrefType "journal-article" @default.
• W2968865251 hasAuthorship W2968865251A5003069566 @default.
• W2968865251 hasAuthorship W2968865251A5005131876 @default.
• W2968865251 hasAuthorship W2968865251A5005692190 @default.
• W2968865251 hasAuthorship W2968865251A5006531968 @default.
• W2968865251 hasAuthorship W2968865251A5016817730 @default.
• W2968865251 hasAuthorship W2968865251A5020721777 @default.
• W2968865251 hasAuthorship W2968865251A5024217548 @default.
• W2968865251 hasAuthorship W2968865251A5031247732 @default.
• W2968865251 hasAuthorship W2968865251A5036040616 @default.
• W2968865251 hasAuthorship W2968865251A5049870109 @default.
• W2968865251 hasAuthorship W2968865251A5052746767 @default.
• W2968865251 hasAuthorship W2968865251A5053223983 @default.
• W2968865251 hasAuthorship W2968865251A5053940370 @default.
• W2968865251 hasAuthorship W2968865251A5060838933 @default.
• W2968865251 hasAuthorship W2968865251A5063050740 @default.
• W2968865251 hasAuthorship W2968865251A5065234124 @default.
• W2968865251 hasAuthorship W2968865251A5071336872 @default.
• W2968865251 hasAuthorship W2968865251A5071788036 @default.
• W2968865251 hasAuthorship W2968865251A5071939716 @default.
• W2968865251 hasAuthorship W2968865251A5077757435 @default.
• W2968865251 hasAuthorship W2968865251A5079888031 @default.
• W2968865251 hasAuthorship W2968865251A5079948354 @default.
• W2968865251 hasAuthorship W2968865251A5081443430 @default.
• W2968865251 hasAuthorship W2968865251A5087643252 @default.
• W2968865251 hasBestOaLocation W29688652511 @default.
• W2968865251 hasConcept C126322002 @default.
• W2968865251 hasConcept C141071460 @default.
• W2968865251 hasConcept C143998085 @default.
• W2968865251 hasConcept C2776364478 @default.
• W2968865251 hasConcept C2776611710 @default.
• W2968865251 hasConcept C2776694085 @default.
• W2968865251 hasConcept C2776755627 @default.
• W2968865251 hasConcept C2776999253 @default.
• W2968865251 hasConcept C2777408962 @default.
• W2968865251 hasConcept C2777478702 @default.
• W2968865251 hasConcept C2779609412 @default.
• W2968865251 hasConcept C2780401358 @default.

• next